TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24444658
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily + PegIFN/RBV (QUAD B2)
Study: 24444658
Drug: Asunaprevir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asunaprevir (200 mg) twice-daily + ribavirin (TRIPLE B3)
Study: 20063238
Drug: Zestra (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zestra (topical botanical preparation)
Study: 18280328
Drug: Six doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six doses of activated charcoal (50 g each at 4-hour intervals)
Study: 18280328
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of activated charcoal (50 g)
Study: 12687557
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg body weight) at weeks 0, 2, and 6
Study: 8545692
Drug: Bolus fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus fluid therapy
Study: 1878583
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX: 12 g/m2 as 4-hour infusion)
Study: 1878583
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (IDMTX: 1 g/m2 as 36-hour infusion)
Study: 1878583
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with daily oral thioguanine and biweekly intravenous (IV) MTX
Study: 6617676
Drug: Hydralazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (mean 127 mg/day, range 37-225)
Study: 29889597
Drug: Brain-targeted treatment
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain-targeted treatment (BT) phase (left/right judgments and touch discrimination training)
Study: 29889597
Drug: No-treatment phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment phase
Study: 15965311
Drug: LY450139 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (50 mg/day for 14 days)
Study: 15965311
Drug: LY450139 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (5 mg, 20 mg, 40 mg doses)
Study: 15965311
Drug: LY450139 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (50 mg/day)
Study: 15965311
Drug: LY450139 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY450139 (all doses)
Study: 11086589
Drug: Arizona Pilot
Normalized name: Arizona ash pollen extract
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arizona Pilot Project treatment (capitation)
Study: 11086589
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment administration sites
Study: 9071904
Drug: Fenretinide (4-HPR)
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (4-HPR) 200 mg/day
Study: 7690396
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G-CSF) 5 micrograms/Kg/day
Study: 31880804
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) added to standard front-line chemotherapy
Study: 28012706
Drug: Methylphenidate (30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (30mg single dose)
Study: 21823414
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Carbamazepine)
Study: 17262141
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - no treatment (G6)
Study: 14586718
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (23 patients)
Study: 8459060
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (8.0 +/- 2.0 mg/liter)
Study: 30282349
Drug: Core stability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stability exercises in addition to traditional treatment (infrared radiation and continuous ultrasound)
Study: 30282349
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (infrared radiation and continuous ultrasound)
Study: 30282349
Drug: Core stability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stability exercises in addition to traditional treatment
Study: 29185931
Drug: J‐aggregated zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: J‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Study: 29185931
Drug: H‐aggregated zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Study: 26109247
Drug: PEERS program
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEERS program (treatment group, n = 12)
Study: 26109247
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control (control group, n = 10)
Study: 22264206
Drug: Individualized oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized oral instruction
Study: 22264206
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral instruction
Study: 17524880
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 10 mg/d, 15 patients
Study: 17524880
Drug: Losartan (L)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (L) 50 mg/d, 20 patients
Study: 17524880
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + Losartan (E+L) 10 mg/d + 50 mg/d, 13 patients
Study: 17524880
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication), 22 patients
Study: 2796623
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 20 mL of 2% lidocaine + 3 mL normal saline
Study: 2796623
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 20 mL of 2% lidocaine + 1:200000 epinephrine + 5 mL normal saline
Study: 2796623
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 20 mL of 2% lidocaine + 2 mL of fentanyl + 3 mL normal saline
Study: 2796623
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 20 mL of 2% lidocaine + 5 mL normal saline
Study: 266502
Drug: Monthly professional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly professional mechanical tooth cleaning
Study: 29851985
Drug: RBV (Ribavirin)
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV (Ribavirin) in combination with ombitasvir/paritaprevir/ritonavir and dasabuvir
Study: 29851985
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment (ombitasvir/paritaprevir/ritonavir and dasabuvir)
Study: 27029846
Drug: Elvitegravir (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elvitegravir (reduced dose of 85 mg) co-administered with cobicistat and atazanavir
Study: 17629069
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg) thrice daily for 4 weeks
Study: 15059101
Drug: Oral nickel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nickel exposure (4 mg)
Study: 11454246
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin
Study: 11454246
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin plus vector control
Study: 9736230
Drug: Calcium polycarbophil
Normalized name: Calcium Polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium polycarbophil (0.62 g/twice daily)
Study: 7988625
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol (1 mg)
Study: 7988625
Drug: Intravenous butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous butorphanol (1 mg)
Study: 7988625
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and transnasal administration
Study: 2919094
Drug: Antiprostaglandin agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiprostaglandin agents (naproxen)
Study: 2919094
Drug: Antiprostaglandin agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiprostaglandin agents (pirprofen)
Study: 2919094
Drug: Antiprostaglandin agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiprostaglandin agents (active treatment)
Study: 29017595
Drug: Locally produced
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally produced enalapril (5-20 mg once daily for 14 days)
Study: 29017595
Drug: Imported enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported enalapril (5-20 mg once daily for 14 days)
Study: 15800157
Drug: Antidepressant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant plus olanzapine
Study: 1742537
Drug: Resumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resumption of interferon at the same dosage after relapse
Study: 7201436
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser treatment for pigment epithelial detachments (6 eyes)
Study: 7201436
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser treatment for subretinal neovascular membranes (7 eyes)
Study: 28573743
Drug: Ixekizumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80 mg as one injection every 4 weeks)
Study: 28573743
Drug: Ixekizumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80 mg as one injection every 2 weeks)
Study: 25080876
Drug: IA clodronate
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA clodronate 2 mg
Study: 19459829
Drug: 10-mg metoclopramide
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg metoclopramide ODT
Study: 19459829
Drug: Conventional 10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 10-mg metoclopramide tablet
Study: 17470680
Drug: Capecitabine in
Normalized name: Product containing capecitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine in combination with lapatinib
Study: 17470680
Drug: Capecitabine in
Normalized name: Product containing capecitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine in combination with trastuzumab
Study: 17470680
Drug: Capecitabine in
Normalized name: Product containing capecitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine in combination with bevacizumab
Study: 9693891
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral gastroscopy
Study: 7943066
Drug: Amnioinfusion (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion (800 ml bolus of normal saline followed by continuous infusion at 180 ml/hr)
Study: 3211167
Drug: Aminophyllin treatment
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophyllin treatment administered orally for one week
Study: 3211167
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aminophyllin treatment)
Study: 3211167
Drug: Aminophyllin treatment
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophyllin treatment continued for at least 6 weeks, followed by monitoring one week after discontinuation
Study: 30422942
Drug: Parent-directed tablet
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-directed tablet computer distraction
Study: 30422942
Drug: Parent-directed tablet
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-directed tablet computer distraction (unrestrained)
Study: 29637918
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 2000IU/day for 6 months
Study: 28877949
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg subcutaneous for 5 days
Study: 28877949
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone 120 mg
Study: 23645012
Drug: Thrombin solution
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin solution (n=10)
Study: 19398604
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg on the first day and then 75 mg once daily for 3 consecutive days)
Study: 7955806
Drug: Prazosin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.25 to 1.0 mg)
Study: 2701751
Drug: Sodium salt
Normalized name: Hepes Sodium Salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salt of L‐thyroxine (L‐T4)
Study: 29147070
Drug: Psychobiotics oral
Normalized name: ambutonium and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychobiotics oral suspension group (POSG)
Study: 29147070
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment group (DTG)
Study: 26305617
Drug: TZD discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZD discontinuation for 1-2 years
Study: 26305617
Drug: TZD discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZD discontinuation for >2 years
Study: 26305617
Drug: TZD use
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZD use and discontinuation
Study: 21699951
Drug: 9 μg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 μg HA/strain TIV ID
Study: 21699951
Drug: 6 μg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 μg HA/strain TIV ID
Study: 21699951
Drug: 3 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg HA/strain TIV ID
Study: 21699951
Drug: 6 μg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 μg HA/strain TIV ID (50-64 years subgroup)
Study: 21699951
Drug: Standard 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 15 μg HA/strain TIV IM
Study: 21699951
Drug: ID administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID administration
Study: 21699951
Drug: TIV ID
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV ID administration experience
Study: 18298480
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BNP and pneumonia severity index (PSI)
Study: 8829417
Drug: Lidocaine 70
Normalized name: lidocaine 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 70 mg in 7.5% glucose
Study: 8829417
Drug: Meperidine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 60 mg in saline
Study: 1640755
Drug: Random CO2
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random CO2 inhalation
Study: 1640755
Drug: Simultaneous CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous CO2 inhalation and exercise
Study: 6340511
Drug: Single MCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single MCA injection
Study: 6340511
Drug: Single MCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single MCA injection after uterine lavage
Study: 6340511
Drug: Two MCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two MCA injections 1 month apart
Study: 26091383
Drug: Subantimicrobial, modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial, modified-release (MR) Doxycycline 40 mg
Study: 19531281
Drug: Cerebrolysin (Cere)
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (Cere) 10, 30 or 60 ml for 12 weeks
Study: 19531281
Drug: Cerebrolysin (Cere)
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (Cere) 60 ml
Study: 15390050
Drug: Ropinirole (0.25-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.25-4.0 mg/day)
Study: 8058422
Drug: Acetazolamide (ACTZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (ACTZ; 5 mg/kg/dose Q6h for 36 hr)
Study: 8058422
Drug: Aminophylline (AMINO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (AMINO; 8 mg/kg bolus then 2.5 mg/kg Q12h for 36 hr)
Study: 27999118
Drug: Oral Contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptives (OCs) induced menses
Study: 26711755
Drug: Daptomycin 8
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 8 mg/kg/day
Study: 26711755
Drug: Daptomycin 10
Normalized name: daptomycin 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 10 mg/kg/day
Study: 26711755
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg/day to 10 mg/kg/day
Study: 22164808
Drug: Equine-assisted activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-assisted activities (therapeutic riding treatment)
Study: 16710114
Drug: 16.5 mg
Normalized name: thymol 16.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.5 mg D9‐tétrahydrocannabinol (THC)
Study: 16710114
Drug: 45.7 mg
Normalized name: menthol 45.7 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45.7 mg THC as a cannabis milk decoction
Study: 12705062
Drug: Rofecoxib (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5 mg daily)
Study: 12705062
Drug: Meloxicam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5 mg daily)
Study: 12705062
Drug: Gastro-protective agents
Normalized name: PROTECTIVE AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-protective agents (proton pump inhibitors or misoprostol)
Study: 9082601
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (10-30 mg 4 times a day)
Study: 1431010
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg daily, increased to 30 mg after 1 week)
Study: 1431010
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg daily, increased to 100 mg after 1 week)
Study: 3904312
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bromocriptine per os
Study: 31395229
Drug: Intra-umbilical vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-umbilical vein injection of carbetocin (1 mL containing 100 μg carbetocin diluted in 20 mL normal saline 0.9%)
Study: 31395229
Drug: Intra-umbilical vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-umbilical vein injection of oxytocin (20 IU diluted in 20 mL normal saline 0.9%)
Study: 28895655
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (titrated doses targeting fasting normoglycaemia)
Study: 24910271
Drug: Deep bolus
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep bolus injection into the mid‐ to lateral cheek
Study: 24910271
Drug: Local mid‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local mid‐ to deep dermal injection into the nasolabial fold
Study: 24910271
Drug: Both deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both deep injection into the mid‐ to lateral cheek and local mid‐ to deep dermal injection into the nasolabial fold
Study: 22399125
Drug: Bupivacaine combined
Normalized name: bupivacaine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine combined with low dose fentanyl (Group B)
Study: 22399125
Drug: Levobupivacaine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine combined with low dose fentanyl (Group L)
Study: 18184902
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein diet (0.8 g protein/kg body weight; 35% animal proteins, 35% textured soy protein, 30% vegetable proteins)
Study: 7586939
Drug: Lys(B28), Pro(B29)-human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lys(B28), Pro(B29)-human insulin (lispro)
Study: 2179176
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g suspension, 4 times a day orally)
Study: 2179176
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene (control group)
Study: 30677455
Drug: Crossover subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover subjects from control to active treatment
Study: 23984182
Drug: EFT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFT treatment
Study: 9433422
Drug: BNP concentration
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP concentration of 17.9 pg/mL or more
Study: 8017305
Drug: Cardiac catheterization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac catheterization with heparin
Study: 8017305
Drug: Peripheral angiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral angiography without heparin